Published in Mol Immunol on April 28, 2015
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. Theranostics (2016) 1.03
Site-Specifically Labeled Immunoconjugates for Molecular Imaging-Part 1: Cysteine Residues and Glycans. Mol Imaging Biol (2016) 0.85
Differential structured illumination microendoscopy for in vivo imaging of molecular contrast agents. Proc Natl Acad Sci U S A (2016) 0.82
Diverse Applications of Nanomedicine. ACS Nano (2017) 0.80
Immuno-PET for Clinical Theranostic Approaches. Int J Mol Sci (2016) 0.80
Site-Specifically Labeled Immunoconjugates for Molecular Imaging-Part 2: Peptide Tags and Unnatural Amino Acids. Mol Imaging Biol (2016) 0.79
Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles. Int J Nanomedicine (2016) 0.78
Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment. Sci Rep (2016) 0.77
Structurally Defined αMHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma. Angew Chem Int Ed Engl (2016) 0.76
Antigen-responsive molecular sensor enables real-time tumor-specific imaging. Theranostics (2017) 0.75
Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging. Front Oncol (2017) 0.75
Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering. Chem Sci (2016) 0.75
Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model. Oncotarget (2016) 0.75
Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen. Int J Mol Sci (2016) 0.75
ImmunoPET Imaging of Murine CD4(+) T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging. Mol Imaging Biol (2016) 0.75
A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors. Theranostics (2017) 0.75
Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl (2001) 19.25
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev (2012) 2.76
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med (2014) 2.54
Tracking immune cells in vivo using magnetic resonance imaging. Nat Rev Immunol (2013) 2.05
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A (2012) 1.99
Imaging macrophages with nanoparticles. Nat Mater (2014) 1.98
A decade of imaging cellular motility and interaction dynamics in the immune system. Science (2012) 1.94
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
Antibody vectors for imaging. Semin Nucl Med (2010) 1.60
Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem (2015) 1.58
A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. J Nucl Med (2013) 1.52
Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging (2013) 1.49
The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol (2014) 1.49
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol (2012) 1.39
Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clin Cancer Res (2014) 1.39
Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem (2009) 1.23
Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics (2013) 1.20
Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF. J Nucl Med (2012) 1.20
Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. J Am Chem Soc (2012) 1.14
Engineered antibodies for molecular imaging of cancer. Methods (2013) 1.14
Protein conjugation with genetically encoded unnatural amino acids. Curr Opin Chem Biol (2013) 1.14
Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). J Med Chem (2014) 1.13
Comparison of a chimeric anti-carcinoembryonic antigen antibody conjugated with visible or near-infrared fluorescent dyes for imaging pancreatic cancer in orthotopic nude mouse models. J Biomed Opt (2013) 1.12
Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chem Commun (Camb) (2012) 1.11
Quantification of lymph node transit times reveals differences in antigen surveillance strategies of naive CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A (2012) 1.10
Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A (2014) 1.10
Theranostic applications of antibodies in oncology. Mol Oncol (2014) 1.06
Potent and specific antitumor effect of CEA-targeted photoimmunotherapy. Int J Cancer (2014) 1.04
Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A (2014) 1.04
Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med (2013) 1.03
Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. J Nucl Med (2014) 1.03
The radiolabeling of proteins by the [18F]AlF method. Appl Radiat Isot (2011) 0.98
In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores. Breast Cancer Res (2012) 0.97
Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV). Chemistry (2014) 0.97
Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody. J Nucl Med (2014) 0.93
Non-invasive imaging of adaptive immunity using positron emission tomography. Immunol Rev (2008) 0.92
H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu. Dalton Trans (2014) 0.91
Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Mol Pharm (2014) 0.91
Pretargeted imaging using bioorthogonal chemistry in mice. Curr Opin Chem Biol (2014) 0.90
Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. Clin Cancer Res (2014) 0.89
Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology (2012) 0.88
Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. Mol Imaging Biol (2012) 0.87
Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging. J Biomed Opt (2013) 0.87
Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation. Protein Eng Des Sel (2014) 0.87
MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int J Nanomedicine (2014) 0.86
Spraying quantum dot conjugates in the colon of live animals enabled rapid and multiplex cancer diagnosis using endoscopy. ACS Nano (2014) 0.85
Antibody-based imaging strategies for cancer. Cancer Metastasis Rev (2014) 0.84
Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging. PLoS One (2012) 0.84
Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging. Bioconjug Chem (2014) 0.84
Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int (2014) 0.84
Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther (2014) 0.84
Non-invasive optical imaging of eosinophilia during the course of an experimental allergic airways disease model and in response to therapy. PLoS One (2014) 0.83
Near-infrared emitting fluorescent nanocrystals-labeled natural killer cells as a platform technology for the optical imaging of immunotherapeutic cells-based cancer therapy. Nanotechnology (2009) 0.83
Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody. Prostate (2014) 0.83
SPECT- and fluorescence image-guided surgery using a dual-labeled carcinoembryonic antigen-targeting antibody. J Nucl Med (2014) 0.83
Use of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET. J Nucl Med (2014) 0.82
Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors. Bioconjug Chem (2014) 0.82
Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging. Bioconjug Chem (2014) 0.82
A bioorthogonal (68)Ga-labelling strategy for rapid in vivo imaging. Chem Commun (Camb) (2014) 0.82
64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proc Natl Acad Sci U S A (2015) 0.81
ImmunoPET imaging of phosphatidylserine in pro-apoptotic therapy treated tumor models. Nucl Med Biol (2012) 0.81
Matching the decay half-life with the biological half-life: ImmunoPET imaging with (44)Sc-labeled cetuximab Fab fragment. Bioconjug Chem (2014) 0.81
64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One (2014) 0.81
A versatile technique for the in vivo imaging of human tumor xenografts using near-infrared fluorochrome-conjugated macromolecule probes. PLoS One (2013) 0.80
Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res (2013) 0.80
Targeting FcRn for the modulation of antibody dynamics. Mol Immunol (2015) 0.80
99mTc-cAbVCAM1-5 imaging is a sensitive and reproducible tool for the detection of inflamed atherosclerotic lesions in mice. J Nucl Med (2014) 0.80
Prostate stem cell antigen antibody-conjugated multiwalled carbon nanotubes for targeted ultrasound imaging and drug delivery. Biomaterials (2014) 0.80
Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo. Mol Pharm (2014) 0.80
Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo. J Nucl Med (2014) 0.79
In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies. Contrast Media Mol Imaging (2014) 0.79
Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor. J Nucl Med (2014) 0.79
Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochem Biophys Res Commun (2013) 0.78
Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. Contrast Media Mol Imaging (2014) 0.78
Metabolic exploitation of the sialic acid biosynthetic pathway to generate site-specifically labeled antibodies. Glycobiology (2013) 0.77
One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials (2014) 0.77
Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft. Mol Pharm (2014) 0.77
Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET. PLoS One (2013) 0.77
Imaging RAGE expression in atherosclerotic plaques in hyperlipidemic pigs. EJNMMI Res (2014) 0.77
Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1. Mol Imaging Biol (2014) 0.76
Visualizing inflammation activity in rheumatoid arthritis with Tc-99 m anti-CD4-mAb fragment scintigraphy. Nucl Med Biol (2014) 0.76
Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates. Mol Imaging (2014) 0.76
Preparation and Evaluation of 99mTc-labeled anti-CD11b Antibody Targeting Inflammatory Microenvironment for Colon Cancer Imaging. Chem Biol Drug Des (2014) 0.76